clinical manifestations and diagnosis of osteoporosis

39
Clinical manifestations and diagnosis of osteoporosis

Upload: godfrey-west

Post on 26-Dec-2015

224 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Clinical manifestations and diagnosis of osteoporosis

Clinical manifestations and diagnosis of osteoporosisClinical manifestations and diagnosis of osteoporosis

Page 2: Clinical manifestations and diagnosis of osteoporosis

2

• INTRODUCTION — Osteoporosis is the most common bone disease.

• DEFINITION — Osteoporosis is a skeletal disorder characterized by two elements:

• low bone mass• and microarchitectural disruption.

Page 3: Clinical manifestations and diagnosis of osteoporosis

3

• There are fewer bony spicules in osteoporotic bone and they are thinner

• But the bone that is present is normally mineralized,

Page 4: Clinical manifestations and diagnosis of osteoporosis

4

• EPIDEMIOLOGY• It is estimated that over 1.3 million osteoporotic

fractures in the United States. • One-half are vertebral fractures, • One-quarter are hip fractures, • And one-quarter are Colles' fractures.• Among subjects age 90 years, 33 percent of women

and 17 percent of men will have a hip fracture .• After age 50 years, a woman is three times more

likely than a man to have a vertebral or hip fracture

Page 5: Clinical manifestations and diagnosis of osteoporosis

5

• Risk Factors For Osteoporosis:• Age.• Sex.• Organs Failure.• Certain drugs include glucocorticoids, heparin,

cyclosporine, medroxyprogesterone acetate, vitamin A and certain synthetic retinoids, Anxiolytic, anticonvulsant, or neuroleptic drugs.

• Organ transplantation .• Cancer treatment.• Vitamin B12 deficiency

Page 6: Clinical manifestations and diagnosis of osteoporosis

6

• Previous fracture between the ages of 20 and 50. years

• History of fracture in a first degree relative.• Cigarette smoking .• Inflammatory bowel disease.• Sedentary life style.• Consumption of large amounts of caffeine.• Above average height.• Low body weight or weight loss.• Type 2 diabetes mellitus .

Page 7: Clinical manifestations and diagnosis of osteoporosis

7

Clinical ManifestationsClinical Manifestations

• Osteoporosis has no clinical manifestations until there is a fracture.

• many patients with achy hips or feet do not have osteoporetic fractures but they have osteomalacia .

• Vertebral fracture• Vertebral fracture is the most common• Most of these fractures (about two-thirds)

are asymptomatic;

Page 8: Clinical manifestations and diagnosis of osteoporosis

• Osteoporotic fracture can lead to the acute onset of pain.

• Successive fractures lead to increased thoracic (dorsal) kyphosis with height loss "dowager's hump“ and complain of "getting fat" without any change in weight.

• Their abdomen becomes protuberant.• The distance from the occiput to the wall

(normally 0 cm).• The size of the gap between the costal margin and

the iliac crest (normally three finger breadths).

8

Page 9: Clinical manifestations and diagnosis of osteoporosis

9

• Other fractures• Hip fractures are relatively common in

osteoporosis, affecting 15 percent of women and five percent of men by 80 years of age.

• RADIOGRAPHIC FEATURES• Plain radiographs show detectable changes

when bone loss exceeds 30 percent.• An early manifestation is "codfish" vertebrae.

Page 10: Clinical manifestations and diagnosis of osteoporosis

10

Page 11: Clinical manifestations and diagnosis of osteoporosis

11

• DIAGNOSIS • MEASUREMENT OF BONE DENSITY:• Several different methods are used to

measure bone density :• Single-photon absorptiometry;wich can

be used only at peripheral sites (radius and calcaneus).

• Dual-photon absorptiometry (DPA) that measure bone density at the spine and hip

Page 12: Clinical manifestations and diagnosis of osteoporosis

12

•  Dual x-ray absorptiometry(DEXA):• The two photons are emitted from an x-ray

tube instead of a radioactive source.

• DXA is the most popular method for measuring bone density at the spine and hip and some times at distal of radious bone.

Page 13: Clinical manifestations and diagnosis of osteoporosis

13

•  Ultrasonography• Potential advantages include lower expense,

portability, and lack of radiation exposure. • Measurements are usually made at the

patella or calcaneus (heel).• Quantitative ultrasound is a good predictor

of fracture risk especially in pregnancy.• A major limitation to using is that the criteria

for diagnosing osteoporosis and recommending treatment are not yet well established.

Page 14: Clinical manifestations and diagnosis of osteoporosis

14

Which Skeletal Sites Should Be Measured?

Which Skeletal Sites Should Be Measured?

Every Patient• Spine

• L2-L4

• Hip• Total Proximal Femur

• Osteoporosis• Femoral Neck• Trochanter

Some Patients

• Forearm (33% Radius)• If hip or spine cannot

be measured• Hyperparathyroidism• Very obese

Use lowest T-score of these sites

Page 15: Clinical manifestations and diagnosis of osteoporosis

15

Indications For Bone Density Testing

Indications For Bone Density Testing

• All women age 55 and older

• All men age 65 and older

• Adults with a fragility fracture• Adults with a disease or condition

associated with low bone density

• Adults taking medication associated with low bone density

• To monitor treatment effect

Page 16: Clinical manifestations and diagnosis of osteoporosis

16

DEFINITIONSDEFINITIONS

• Osteopenia• Bone mineral density (BMD)

measurement at any site > 1 but 2.5 standard deviations below the young adult standard

• T score < -1 but -2.5

Page 17: Clinical manifestations and diagnosis of osteoporosis

17

DefinitionsDefinitions

• Osteoporosis• BMD measurement at any site

> 2.5 standard deviations below the young adult standard with or without previous fracture

• T score of < -2.5

Page 18: Clinical manifestations and diagnosis of osteoporosis

WHO Study Group. 1994. 18

Diagnostic ClassificationDiagnostic Classification

Classification T-score

Normal -1 or greater

Osteopenia Between -1 and -2.5

Osteoporosis -2.5 or less

Severe Osteoporosis-2.5 or less and fragility fracture

Page 19: Clinical manifestations and diagnosis of osteoporosis

19

SCREENING FOR SECONDARY CAUSESSCREENING FOR SECONDARY CAUSES

Disease Recommended Laboratory Tests(bolded items are recommended routinely)

Cushing’s disease Electrolytes, 24-hour urinary cortisol

Hyperthyroidism TSH, T4

Hypogonadism Bioavailable testosterone

Multiple myeloma CBC, serum electrophoresis, urine electrophoresis

Osteomalacia Alkaline phosphatase, 25(OH)D

Paget’s disease Alkaline phosphatase

Primary hyperparathyroidism Calcium, PTH

Page 20: Clinical manifestations and diagnosis of osteoporosis

20

Page 21: Clinical manifestations and diagnosis of osteoporosis

21

Page 22: Clinical manifestations and diagnosis of osteoporosis

22

Page 23: Clinical manifestations and diagnosis of osteoporosis

23

Page 24: Clinical manifestations and diagnosis of osteoporosis

24

Page 25: Clinical manifestations and diagnosis of osteoporosis

25

Treatment GuidelinesTreatment Guidelines

Patient Profile T-score

NOF AACE

No Risk Factors Less than -2.0 -2.5 or less

Risk Factors† Less than -1.5 -1.5 or less

† Fragility fracture, family history of fracture, cigarette smoking, low body weight (<127 lbs.), etc.

Summary of recommendations for pharmacologic therapy according to T-score from the National Osteoporosis Foundation (NOF) and the American Association of Clinical Endocrinologists (AACE)

Page 26: Clinical manifestations and diagnosis of osteoporosis

26

RISK FACTORS FOR POSTMENOPAUSAL WOMEN

RISK FACTORS FOR POSTMENOPAUSAL WOMEN

• Early menopause• White or Asian race• Sedentary life style• Smoking• Small frame• Alcohol abuse• Primary hyperparathyroidism• Hyperthyroidism• Glucocorticoid use

Page 27: Clinical manifestations and diagnosis of osteoporosis

27

Page 28: Clinical manifestations and diagnosis of osteoporosis

28

CALCIUM & VITAMIN DCALCIUM & VITAMIN D

• Calcium and vitamin D maintain or increase bone density & help prevent hip and nonvertebral fractures

• Men 65 years and older & postmenopausal women should ingest a total of 800 IU of vitamin D and 1200 mg / day of calcium daily.

• Higher doses are required if they have malabsorption or rapid metabolism of vitamin D

Page 29: Clinical manifestations and diagnosis of osteoporosis

29

Estrogen/progestin therapyEstrogen/progestin therapy

• Estrogen-progestin therapy is no longer a first-line approach because of Increased risk of :

• Breast cancer, • Stroke, • Venous thromboembolism, • And perhaps coronary disease. • HRT Prevents bone loss at hip & spine

when initiated within 10 years of menopause

Page 30: Clinical manifestations and diagnosis of osteoporosis

30

• Possible indications for estrogen-progestin in postmenopausal women include persistent menopausal symptoms and…

• women with an indication for antiresorptive therapy who cannot tolerate the other drugs or because of side effects.

• There was a significant 33 percent reduction in clinical vertebral fractures and a 23 percent reduction in other osteoporotic fractures.

Page 31: Clinical manifestations and diagnosis of osteoporosis

31

Bisphosphonates Bisphosphonates

• Alendronate (10 mg/day or 70 mg once weekly) or risedronate (5 mg/day or 35 mg once weekly), are good choices for the treatment of women with established osteoporosis.

• These drugs increase bone mass and reduce the incidence of vertebral and nonvertebral fractures (even in women who already have fractures).

Page 32: Clinical manifestations and diagnosis of osteoporosis

32

• The beneficial effects of alendronate persist over several years after treatment is stopped,

• When given, alendronate or risedronate should be taken with precautions to avoid pill-induced esophagitis.

• Alendronate appears to be well tolerated and effective for at least ten years .

Page 33: Clinical manifestations and diagnosis of osteoporosis

33

OTHER BISPHOSPHONATES

OTHER BISPHOSPHONATES

• Residronate (Actonel)• Approved for osteoporosis prevention & treatment

of osteoporosis: 5 mg / day• In comparison with placebo:

• bone density of spine & hip• new vertebral fracture rate

• GI side effects

• Zolindronic acid(Aclasta)• Only infusible drug approved for treatment of

osteoporosis and the most strong members.• Use for idiopathic osteoporosis only if other

treatments are ineffective or conterindicated.

Page 34: Clinical manifestations and diagnosis of osteoporosis

34

SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)

SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)

• Act as estrogen agonists in bone and heart.

• Act as estrogen antagonists in breast and uterine tissue

• Potential for preventing osteoporosis without the increased risk of breast or uterine cancer

Page 35: Clinical manifestations and diagnosis of osteoporosis

35

SERMs: RALOXIFENESERMs: RALOXIFENE

• Rationale• Approved for osteoporosis prevention &

treatment in postmenopausal women• In comparison with placebo:

• vertebral fractures by 60%• breast cancer (relative risk 0.24)• bone turnover & maintained hip & total body

bone density• total cholesterol and LDL levels

• Side effects• Flu-like symptoms, hot flushes, leg cramps• Peripheral edema

Page 36: Clinical manifestations and diagnosis of osteoporosis

36

CalcitoninCalcitonin

• A less popular choice for treatment of osteoporosis is nasal calcitonin, 200 IU/day.

• It is a weak drug for treatment and because of tachyphylaxis has a little effect on density.

• There is one exception,most use calcitonin as first-line therapy in patients who have substantial pain from an acute osteoporotic fracture.

• Dosing• Subcutaneous injection• Nasal spray (fewer reported side effects,

Page 37: Clinical manifestations and diagnosis of osteoporosis

37

Monitoring of treatmentMonitoring of treatment

• Bone density measurement can be repeated after one year of therapy.

• If BMD is stable or improving, that would be evidence for treatment response.

• However, if BMD declines at one year, compliance with drug, calcium and vitamin D should be verified, and some evaluation for secondary causes of bone loss should be performed .

• If the patient is otherwise well and taking the drug and supplements correctly, the correct action is controversial.

Page 38: Clinical manifestations and diagnosis of osteoporosis

38

• Some physicians believe that the decrease in BMD truly reflects a treatment failure and would consider modification of the primary treatment for the osteoporosis.

• Others believe that the decline in BMD is not necessarily reflecting inadequate therapy, but could be ascribed to measurement error and would repeat BMD one year later, taking action only if the decline is reaffirmed.

Page 39: Clinical manifestations and diagnosis of osteoporosis

39